Assets
| Type | Time | Amount | Unit |
|---|---|---|---|
| ifrs-full:Assets | 2023-12-31 | 28391000000 | dkk |
| ifrs-full:Assets | 2022-12-31 | 27983000000 | dkk |
Revenue
| Type | Start date | End date | Amount | Unit |
|---|---|---|---|---|
| ifrs-full:Revenue | 2023-01-01 | 2023-12-31 | 17899000000 | dkk |
| ifrs-full:Revenue | 2022-01-01 | 2022-12-31 | 17553000000 | dkk |
XML
See the xml submitted here:
XML: http://regnskaber.virk.dk/72170001/amNsb3VkczovLzAzL2NmLzJhLzdiLzE0LzIzMzktNGQ0OC04NTJkLTMxMjdiMjFmZDUwOA.xml
Separator
The full data:
<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance"
xmlns="http://www.w3.org/1999/xhtml"
xmlns:arr="http://xbrl.dcca.dk/arr"
xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12"
xmlns:cmn="http://xbrl.dcca.dk/cmn"
xmlns:sob="http://xbrl.dcca.dk/sob"
xmlns:link="http://www.xbrl.org/2003/linkbase"
xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full"
xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
xmlns:ix="http://www.xbrl.org/2013/inlineXBRL"
xmlns:mrv="http://xbrl.dcca.dk/mrv"
xmlns:NOV="http://xbrl.novozymes.com/2023-12-31"
xmlns:fsa="http://xbrl.dcca.dk/fsa"
xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
xmlns:gsd="http://xbrl.dcca.dk/gsd"
xmlns:xlink="http://www.w3.org/1999/xlink"
id="DKGAAP"
xml:lang="en">
<link:schemaRef xlink:href="http://archprod.service.eogs.dk/taxonomy/20221001/entryDanishGAAPExcludingBalanceSheetIncomeStatementIncludingManagementsReview20221001.xsd"
xlink:type="simple"/>
<xbrli:context id="ctx-1">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-37">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2023-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-2">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx-5">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2023-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx-52">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-01-01</xbrli:startDate>
<xbrli:endDate>2022-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-38">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
<cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-39">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
<cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-40">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-41">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-42">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>3</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-43">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>4</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-44">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>5</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-45">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>6</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-46">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>7</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-47">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>8</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-48">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>9</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-49">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>10</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-51">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
<cmn:auditorIdentifier>2</cmn:auditorIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-50">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">529900T6WNZXD2R3JW38</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
<cmn:auditorIdentifier>1</cmn:auditorIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:unit id="pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<gsd:NameOfSubmittingEnterprise contextRef="ctx-1" id="s9_notesesefdkgaap__7__7" xml:lang="en">Novozymes A/S</gsd:NameOfSubmittingEnterprise>
<gsd:NameOfReportingEntity contextRef="ctx-1" id="s9_notesesefdkgaap__7__6" xml:lang="en">Novozymes A/S</gsd:NameOfReportingEntity>
<gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx-1" id="s9_notesesefdkgaap__7__9">10007127</gsd:IdentificationNumberCvrOfReportingEntity>
<gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx-1" id="s9_notesesefdkgaap__7__10">10007127</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
<gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx-1" id="s9_notesesefdkgaap__7__19" xml:lang="en">Krogshoejvej 36</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
<gsd:AddressOfReportingEntityStreetName contextRef="ctx-1" id="s9_notesesefdkgaap__7__15" xml:lang="en">Krogshoejvej</gsd:AddressOfReportingEntityStreetName>
<gsd:AddressOfReportingEntityStreetBuildingIdentifier contextRef="ctx-1" id="s9_notesesefdkgaap__7__16" xml:lang="en">36</gsd:AddressOfReportingEntityStreetBuildingIdentifier>
<gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx-1" id="s9_notesesefdkgaap__7__20" xml:lang="en">2880 Bagsvaerd</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
<gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="ctx-1" id="s9_notesesefdkgaap__7__17" xml:lang="en">2880</gsd:AddressOfReportingEntityPostCodeIdentifier>
<gsd:AddressOfReportingEntityDistrictName contextRef="ctx-1" id="s9_notesesefdkgaap__7__18" xml:lang="en">Bagsvaerd</gsd:AddressOfReportingEntityDistrictName>
<mrv:LinkToStatementOfPolicyForDataEthics contextRef="ctx-37" id="s9_notesesefdkgaap__7__30">https://investors.novozymes.com/investors/corporate-governance/articles-of-association-and-reports-on-corporate-governance/default.aspx</mrv:LinkToStatementOfPolicyForDataEthics>
<mrv:LinkToStatementOfDiversityPolicies contextRef="ctx-1" id="s9_notesesefdkgaap__7__29">https://investors.novozymes.com/investors/corporate-governance/articles-of-association-and-reports-on-corporate-governance/default.aspx</mrv:LinkToStatementOfDiversityPolicies>
<mrv:LinkToCorporateGovernanceReport contextRef="ctx-1" id="s9_notesesefdkgaap__7__28">https://investors.novozymes.com/investors/corporate-governance/articles-of-association-and-reports-on-corporate-governance/default.aspx</mrv:LinkToCorporateGovernanceReport>
<mrv:LinkToStatementOfCorporateSocialResponsibility contextRef="ctx-1" id="s9_notesesefdkgaap__7__27">https://investors.novozymes.com/investors/corporate-governance/articles-of-association-and-reports-on-corporate-governance/default.aspx</mrv:LinkToStatementOfCorporateSocialResponsibility>
<mrv:PrimaryActionsForFulfillmentOfTargetFigureOfUnderrepresentedGenderBoardOfDirectors contextRef="ctx-2" id="s9_notesesefdkgaap__9__39" xml:lang="en">Diversity on the Board of Directors Our policy for diversity and equal opportunities covers the workforce and the Board of Directors. Ambitious diversity targets have been in place for the Board of Directors to ensure the right mix of competencies to address the challenges of a large global company.</mrv:PrimaryActionsForFulfillmentOfTargetFigureOfUnderrepresentedGenderBoardOfDirectors>
<mrv:StatementOfTargetFiguresAndPoliciesForTheUnderrepresentedGender contextRef="ctx-2" id="s9_notesesefdkgaap__9__31-1" xml:lang="en">Diversity on the Board of Directors Our policy for diversity and equal opportunities covers the workforce and the Board of Directors. Ambitious diversity targets have been in place for the Board of Directors to ensure the right mix of competencies to address the challenges of a large global company. The Board Competency Profile reï¬ects the targets that have been defined for all competencies required on the Board of Directors. According to Novozymesâ target on gender diversity for shareholder-elected board members, 40% or more must be female and 40% or more must be male. In 2023, 33% of Novozymesâ shareholder-elected board members were women. Please also refer to the overview of diversity targets for board members elected by shareholders. Despite not meeting our own gender diversity target, the composition of the Board of Directors met the gender diversity requirements set out in Danish legislation, see the table on statutory reporting of gender diversity.Gender diversity at other management levelsOur targets on gender diversity aim to increase the share of the underrepresented gender at all management levels.In accordance with section 99b of the Danish Financial Statements Act, we have a target specifi-cally for âother management levelsâ at Novozymes A/S defined as a first management level, which we identify as the Executive Leadership Team, and a second management level comprising people man-agers of Novozymes A/S reporting to the Execu-tive Leadership Team. Here, we strive to achieve a minimum of 45% women and 45% men at other management levels by 2030. In 2023, the number of employees at other man-agement levels was 38, of which 40% were wom-en. We will continue to work towards a 2030 target for Novonesis. More information on our 2025 and 2030 gender diversity targets globally can be found in Note 8.2 Inclusion & diversity.Measurements and impact The Executive Leadership Team is included in the monitoring of the targets for gender diversity glob-ally. The gender diversity targets are anchored in KPIs across the organization, and there are quar-terly follow-ups on gender diversity in promotions and new hires. Focus on gender diversity is includ-ed in core HR processes and regional roadmaps. Generally, we see an increased focus on gender diversity across our leadership teams, and as an example in 2023, our newest leadership program, Leading Tomorrow, was oîered to an equal num-ber of female and male leadership talents, which provides a gender-balanced leadership talent poolfor the future. Furthermore, to promote gender diversity among leaders in the company, we intro-duced specific requirements in our succession management systems to monitor diversity among the potential successors for leadership positions.</mrv:StatementOfTargetFiguresAndPoliciesForTheUnderrepresentedGender>
<mrv:StatusOfAchievementOfTargetFigureOfUnderrepresentedGenderBoardOfDirectors contextRef="ctx-2" id="s9_notesesefdkgaap__9__44" xml:lang="en">According to Novozymesâ target on gender diversity for shareholder-elected board members, 40% or more must be female and 40% or more must be male. In 2023, 33% of Novozymesâ shareholder-elected board members were women. Please also refer to the overview of diversity targets for board members elected by shareholders. Despite not meeting our own gender diversity target, the composition of the Board of Directors met the gender diversity requirements set out in Danish legislation, see the table on statutory reporting of gender diversity.</mrv:StatusOfAchievementOfTargetFigureOfUnderrepresentedGenderBoardOfDirectors>
<mrv:PrimaryActionsForFulfillmentOfTargetFigureOtherManagementLevels contextRef="ctx-2" id="s9_notesesefdkgaap__9__40-1" xml:lang="en">Gender diversity at other management levelsOur targets on gender diversity aim to increase the share of the underrepresented gender at all management levels.In accordance with section 99b of the Danish Financial Statements Act, we have a target specifi-cally for âother management levelsâ at Novozymes A/S defined as a first management level, which we identify as the Executive Leadership Team, and a second management level comprising people man-agers of Novozymes A/S reporting to the Execu-tive Leadership Team. Here, we strive to achieve a minimum of 45% women and 45% men at other management levels by 2030.Our approachWe are committed to nurture a culture of diversity, equity, and inclusion. By 2030, we aim to achieve gender balance. This means that we will strive for a minimum of 45% women and 45% men across all professionals and in senior management.We recognize that focusing on diversity of rep-resentation alone is not enough. For diverse teams to succeed, people need to feel that they are valued, respected, and have a shared sense of purpose, and thus we focus on inclusion. We take a regional approach to developing and defining programs based on local demographics to address diversity dimensions beyond gender. Many of our sites have Employee Resource Groups which aim to foster Diversity, Equity, and Inclusion (DE&I) locally.At Novozymes, we have a policy for diversity and equal opportunities, which applies to our entire workforce. Our People and Organization (P&O) function, together with regional leaders across Novozymes are responsible for ensuring equal opportunities and for promoting DE&I.</mrv:PrimaryActionsForFulfillmentOfTargetFigureOtherManagementLevels>
<mrv:StatusOfAchievementOfTargetFigureOtherManagementLevels contextRef="ctx-2" id="s9_notesesefdkgaap__9__42-1" xml:lang="en">In 2023, the number of employees at other man-agement levels was 38, of which 40% were wom-en. We will continue to work towards a 2030 target for Novonesis. More information on our 2025 and 2030 gender diversity targets globally can be found in Note 8.2 Inclusion & diversity.2023 summaryIn 2023, our senior management consisted of 215 employees of which 36% were women, an increase compared to 33% in 2022. In addition, gender balance across all professionals remained at 43% women and 57% men, as in 2022. In 2023, we promoted gender diversity among leaders in the company. As an example, our new-est leadership program, Leading Tomorrow, was offered to an equal number of female and male leadership talents, which provides a gender balanced leadership talent pool for the future. Furthermore, we introduced specific require-ments in our succession management systems to monitor diversity among the potential successors for leadership positions.</mrv:StatusOfAchievementOfTargetFigureOtherManagementLevels>
<mrv:TotalNumberOfMembersOfBoardOfDirectorsExcludingEmployeeelectedMembers contextRef="ctx-5"
decimals="0"
id="s9_notesesefdkgaap__9__33"
unitRef="pure">6</mrv:TotalNumberOfMembersOfBoardOfDirectorsExcludingEmployeeelectedMembers>
<mrv:PercentageOfUnderrepresentedGenderBoardOfDirectors contextRef="ctx-5"
decimals="2"
id="s9_notesesefdkgaap__9__34"
unitRef="pure">0.33</mrv:PercentageOfUnderrepresentedGenderBoardOfDirectors>
<mrv:TotalNumberOfOtherManagementLevels contextRef="ctx-5"
decimals="0"
id="s9_notesesefdkgaap__9__35"
unitRef="pure">38</mrv:TotalNumberOfOtherManagementLevels>
<mrv:PercentageOfUnderrepresentedGenderOtherManagementLevels contextRef="ctx-5"
decimals="2"
id="s9_notesesefdkgaap__9__36"
unitRef="pure">0.40</mrv:PercentageOfUnderrepresentedGenderOtherManagementLevels>
<mrv:TargetFigureInPercentageOfUnderrepresentedGenderOtherManagementLevels contextRef="ctx-5"
decimals="2"
id="s9_notesesefdkgaap__9__37"
unitRef="pure">0.45</mrv:TargetFigureInPercentageOfUnderrepresentedGenderOtherManagementLevels>
<mrv:YearOfFulfillmentOfTargetFigureOfUnderrepresentedGenderOtherManagementLevels contextRef="ctx-5" id="s9_notesesefdkgaap__9__38">2030</mrv:YearOfFulfillmentOfTargetFigureOfUnderrepresentedGenderOtherManagementLevels>
<fsa:AverageNumberOfEmployees contextRef="ctx-1" decimals="0" unitRef="pure">6805</fsa:AverageNumberOfEmployees>
<fsa:AverageNumberOfEmployees contextRef="ctx-52" decimals="0" unitRef="pure">6690</fsa:AverageNumberOfEmployees>
<sob:StatementByExecutiveAndSupervisoryBoards contextRef="ctx-1" id="s9_notesesefdkgaap__7__191" xml:lang="en">The Board of Directors and the Executive Management have today considered and approved the Annual Report of Novozymes A/S for the financial year January 1 â December 31, 2023.The Consolidated Financial Statements have been prepared in accordance with International Financial Reporting Standards as adopted by the EU and further requirements in the Danish Financial Statements Act, and the Parent Company Financial Statements have been pre-pared in accordance with the Danish Financial Statements Act. Managementâs Review has been prepared in accordance with the Danish Financial Statements Act and Article 8 of Regulation (EU) 2020/852 (EU Taxonomy Regulation). In our opinion, the accounting policies used are appropriate, and the Groupâs internal controls rel-evant to the preparation and presentation of the Annual Report are adequate. The Consolidated Financial Statements and the Parent Company Financial Statements give a true and fair view of the financial position at December 31, 2023 of the Group and the Parent Company and of the results of the Group and the Parent Company operations and consolidated cash flows for the financial year January 1 â December 31, 2023. In our opinion, Managementâs Review includes a true and fair account of the development in the operations and financial circumstances of the Group and the Parent Company, of the results for the year, and of the financial position of the Group and the Parent Company as well as a description of the most significant risks and elements of uncer-tainty facing the Group and the Parent Company. Novozymesâ consolidated environmental data and the consolidated social and governance data and the related notes have been prepared in accordance with the reporting principles of mate-riality, inclusivity, responsiveness and the accounting policies. In our opinion, they give a true and fair view of the organisationâs environ-mental, social and governance performance in accordance with these principles and policies. In our opinion, the Annual Report of Novozymes A/S for the financial year January 1 - December 31, 2023 with the file name NOVOZYMES-2023-12-31-en.zip has been prepared, in all material respects, in compliance with the ESEF Regulation.We recommend that the Annual Report be adopted at the Annual Shareholdersâ Meeting.</sob:StatementByExecutiveAndSupervisoryBoards>
<sob:PlaceOfSignatureOfStatement contextRef="ctx-1" id="s9_notesesefdkgaap__7__192" xml:lang="en">Bagsvaerd</sob:PlaceOfSignatureOfStatement>
<sob:DateOfApprovalOfAnnualReport contextRef="ctx-1" id="s9_notesesefdkgaap__7__193">2024-02-08</sob:DateOfApprovalOfAnnualReport>
<cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx-38" id="s9_notesesefdkgaap__7__194" xml:lang="en">Ester Baiget</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
<cmn:TitleOfMemberOfExecutiveBoard contextRef="ctx-38" id="s9_notesesefdkgaap__7__195" xml:lang="en">President & CEO</cmn:TitleOfMemberOfExecutiveBoard>
<cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx-39" id="s9_notesesefdkgaap__7__196" xml:lang="en">Rainer Lehmann</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
<cmn:TitleOfMemberOfExecutiveBoard contextRef="ctx-39" id="s9_notesesefdkgaap__7__197" xml:lang="en">CFO</cmn:TitleOfMemberOfExecutiveBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-40" id="s9_notesesefdkgaap__7__198" xml:lang="en">Cornelis (Cees) de Jong</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-40" id="s9_notesesefdkgaap__7__199" xml:lang="en">Chair</cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-41" id="s9_notesesefdkgaap__7__200" xml:lang="en">Kim Stratton</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-41" id="s9_notesesefdkgaap__7__201" xml:lang="en">Vice Chair</cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-42" id="s9_notesesefdkgaap__7__202" xml:lang="en">Heine Dalsgaard</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-43" id="s9_notesesefdkgaap__7__203" xml:lang="en">Sharon James</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-44" id="s9_notesesefdkgaap__7__204" xml:lang="en">Kasim Kutay</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-45" id="s9_notesesefdkgaap__7__205" xml:lang="en">Morten Otto Alexander Sommer</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-46" id="s9_notesesefdkgaap__7__206" xml:lang="en">Anne Breum</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-47" id="s9_notesesefdkgaap__7__207" xml:lang="en">Anders Hentze Knudsen</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-48" id="s9_notesesefdkgaap__7__208" xml:lang="en">Preben Nielsen</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-49" id="s9_notesesefdkgaap__7__209" xml:lang="en">Jens Ãbro</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="ctx-1" id="s9_notesesefdkgaap__7__212" xml:lang="en">To the shareholders of Novozymes A/S</arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements>
<arr:OpinionOnAuditedFinancialStatements contextRef="ctx-1" id="s9_notesesefdkgaap__7__213" xml:lang="en">Our opinionIn our opinion, the Consolidated Financial Statements give a true and fair view of the Groupâs financial position at December 31, 2023 and of the results of the Groupâs operations and cash flows for the financial year January 1 to December 31, 2023 in accordance with IFRS Accounting Standards as adopted by the EU and further requirements in the Danish Financial Statements Act. Moreover, in our opinion, the Parent Company Financial Statements give a true and fair view of the Parent Companyâs financial position at December 31, 2023 and of the results of the Parent Companyâs operations for the financial year January 1 to December 31, 2023 in accord-ance with the Danish Financial Statements Act. In our opinion, the Consolidated environmental data and the Consolidated social and governance data for the financial year January 1 to December 31, 2023 are prepared in accordance with the accounting policies for the Consolidated environmental data and the Consolidated social and governance data. Our opinions are consistent with our Auditorâs Long-form Report to the Audit Committee and the Board of Directors. What we have auditedThe Consolidated Financial Statements of Novozymes A/S, pages 52-60 and 65-123 for the financial year January 1 to December 31, 2023 comprise the consolidated income statement and statement of comprehensive income, the consolidated balance sheet, the consolidated statement of equity, the consolidated cash flow statement and the notes, including material accounting policy information. The Parent Company Financial Statements of Novozymes A/S, pages 155-169 for the financial year January 1 to December 31, 2023 comprise the income statement, the balance sheet, the statement of equity and the notes, including material accounting policy information. These are collectively referred to as the âFinancial Statementsâ. The Consolidated environmental data and the Consolidated social and governance data of Novozymes A/S, pages 61-64 and124-148, for the financial year January 1 to December 31, 2023 comprise the environmental performance and consolidated data, the social and govern-ance performance and consolidated data and the related notes, including material accounting pol-icy information. These are collectively referred to as the âEnvironmental, Social and Governance Data.â</arr:OpinionOnAuditedFinancialStatements>
<arr:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="ctx-1" id="s9_notesesefdkgaap__7__214" xml:lang="en">Basis for opinionWe conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those stand-ards and requirements are further described in the Auditorâs responsibilities for the audit of the Financial Statements and the Environmental, Social and Governance Data section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. IndependenceWe are independent of the Group in accordance with the International Ethics Standards Board for Accountantsâ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark. We have also fulfilled our other ethical responsibilities in accordance with these require-ments and the IESBA Code. To the best of our knowledge and belief, prohib-ited non-audit services referred to in Article 5(1) of Regulation (EU) No 537/2014 were not pro-vided. AppointmentWe were appointed as auditors of Novozymes A/S for the first time after the initial public offer-ing on March 21, 2001. We have been reap-pointed annually by shareholder resolution for a total period of uninterrupted engagement of 23 years, including the financial year 2023.</arr:DescriptionOfQualificationsOfAuditedFinancialStatements>
<arr:KeyAuditMattersAudit contextRef="ctx-1" id="s9_notesesefdkgaap__7__215" xml:lang="en">Key audit mattersKey audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Financial Statements for 2023. These matters were addressed in the con-text of our audit of the Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Key audit matter Revenue recognitionNovozymes has entered into various sales agreements that are sub-ject to interpretation, which increases the inherent complexity of rev-enue recognition. Additionally, the volume of transactions and geo-graphical spread of the Groupâs operations increase complexity, including in respect of occurrence and timing of revenue. We focus on this area because of the significance to the Consolidated Financial Statements, as well as the inherent complexity in both reve-nue recognition and individual sales agreements including different terms therein. Refer to Note 2.2 to the Consolidated Financial Statements.How our audit addressed the key audit matterWe considered the appropriateness of the Groupâs accounting poli-cies for revenue recognition and assessed compliance with applicable financial reporting standards. We performed risk assessment procedures with the purpose of achieving an understanding of IT-systems, business procedures and relevant controls regarding recognition of revenue. In respect of con-trols, we assessed whether they were designed and implemented effectively to address the risk of material misstatement. For selected controls, which we planned to rely on, we tested whether these con-trols had been performed on a consistent basis. We discussed the judgments related to the recognition and classifica-tion of revenue with Management. We performed substantive procedures regarding returns, delivery terms and rebates in order to assess the principles applied for occur-rence and timing of revenue. We applied data analysis in our testing of revenue transactions in order to identify and test transactions outside the ordinary transac-tion flow. Finally, we assessed the adequacy of disclosures relating to revenue recognition.</arr:KeyAuditMattersAudit>
<arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="ctx-1" id="s9_notesesefdkgaap__7__216" xml:lang="en">Statement on Managementâs ReviewManagement is responsible for Managementâs Review, pages 3-51 and 170-171.Our opinion on the Financial Statements and on the Environmental, Social and Governance Data does not cover Managementâs Review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the Financial Statements, our responsibility is to read Managementâs Review and, in doing so, consider whether Managementâs Review is materially inconsistent with the Financial Statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. Moreover, we consider ed whether Managementâs Review includes the disclosures required by the Danish Financial Statements Act and Article 8 of Regulation (EU) 2020/852 (EU Taxonomy Regulation). Based on the work we have performed, in our view, Managementâs Review is in accordance with the Consolidated Financial Statements, the Parent Company Financial Statements and the Environmental, Social and Governance Data and has been prepared in accordance with the requirements of the Danish Financial Statements Act and the disclosure requirements of Article 8 of Regulation (EU) 2020/852 (EU Taxonomy Regulation). We did not identify any material mis-statement in Managementâs Review.</arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements>
<arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="ctx-1" id="s9_notesesefdkgaap__7__217" xml:lang="en">Managementâs responsibilities for the Financial Statements and the Environmental, Social and Governance Data Management is responsible for the preparation of consolidated financial statements that give a true and fair view in accordance with IFRS Accounting Standards as adopted by the EU and further requirements in the Danish Financial Statements Act and for the preparation of parent company financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. Furthermore, Management is responsible for pre-paring the Environmental, Social and Governance Data in accordance with the accounting policies for the Environmental, Social and Governance Data, and for such internal control as Management determines is necessary to enable the preparation of Environmental, Social and Governance Data that are free from material mis-statement, whether due to fraud or error. In preparing the Financial Statements, Management is responsible for assessing the Groupâs and the Parent Companyâs ability to con-tinue as a going concern, disclosing, as applica-ble, matters related to going concern and using the going concern basis of accounting unless Management either intends to liquidate the Group or the Parent Company or to cease opera-tions, or has no realistic alternative but to do so.</arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements>
<arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="ctx-1" id="s9_notesesefdkgaap__7__218" xml:lang="en">Auditorâs responsibilities for the audit of the Financial Statements and the Environmental, Social and Governance Data Our objectives are to obtain reasonable assur-ance about whether the Financial Statements and the Environmental, Social and Governance Data as a whole are free from material misstate-ment, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assur-ance, but is not a guarantee that an audit con-ducted in accordance with ISAs and the addi-tional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements and the Environmental, Social and Governance Data. As part of an audit in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also: ⢠Identify and assess the risks of material mis-statement of the Financial Statements and the Environmental, Social and Governance Data, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, inten-tional omissions, misrepresentations, or the override of internal control. ⢠Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the cir-cumstances, but not for the purpose of expressing an opinion on the effectiveness of the Groupâs and the Parent Companyâs inter-nal control. ⢠Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management. ⢠Conclude on the appropriateness of Managementâs use of the going concern basis of accounting and based on the audit evi-dence obtained, whether a material uncer-tainty exists related to events or conditions that may cast significant doubt on the Groupâs and the Parent Companyâs ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditorâs report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditorâs report. However, future events or conditions may cause the Group or the Parent Company to cease to continue as a going concern. ⢠Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underly-ing transactions and events in a manner that gives a true and fair view.⢠Obtain sufficient appropriate audit evidence regarding the financial information, environ-mental, social and governance data of the entities or business activities within the Group to express an opinion on the Consolidated Financial Statements and the Environmental, Social and Governance Data. We are responsi-ble for the direction, supervision and perfor-mance of the group audit. We remain solely responsible for our audit opinion. We communicate with those charged with gov-ernance regarding, among other matters, the planned scope and timing of the audit and signif-icant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with rel-evant ethical requirements regarding independ-ence, and to communicate with them all relation-ships and other matters that may reasonably be thought to bear on our independence and, where applicable, actions taken to eliminate threats or safeguards applied. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditorâs report unless law or regulation precludes public disclo-sure about the matter.</arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed>
<arr:AuditorsReportOnXbrlTagging contextRef="ctx-1" id="s9_notesesefdkgaap__7__219" xml:lang="en">Report on compliance with the ESEF Regulation As part of our audit of the Financial Statements we performed procedures to express an opinion on whether the annual report of Novozymes A/S for the financial year January 1 to December 31, 2023 with the filename NOVOZYMES-2023-12-31-en.zip is prepared, in all material respects, in compliance with the Commission Delegated Regulation (EU) 2019/815 on the European Single Electronic Format (ESEF Regulation) which includes requirements related to the preparation of the annual report in XHTML format and iXBRL tagging of the Consolidated Financial Statements including notes. Management is responsible for preparing an annual report that complies with the ESEF Regulation. This responsibility includes: ⢠The preparing of the annual report in XHTML format; ⢠The selection and application of appropriate iXBRL tags, including extensions to the ESEF taxonomy and the anchoring thereof to ele-ments in the taxonomy, for all financial infor-mation required to be tagged using judgment where necessary; ⢠Ensuring consistency between iXBRL tagged data and the Consolidated Financial Statements presented in human-readable for-mat; and ⢠For such internal control as Management determines necessary to enable the prepara-tion of an annual report that is compliant with the ESEF Regulation. Our responsibility is to obtain reasonable assur-ance on whether the annual report is prepared, in all material respects, in compliance with the ESEF Regulation based on the evidence we have obtained, and to issue a report that includes our opinion. The nature, timing and extent of proce-dures selected depend on the auditorâs judg-ment, including the assessment of the risks of material departures from the requirements set out in the ESEF Regulation, whether due to fraud or error. The procedures include: ⢠Testing whether the annual report is pre-pared in XHTML format; ⢠Obtaining an understanding of the companyâs iXBRL tagging process and of internal control over the tagging process; ⢠Evaluating the completeness of the iXBRL tagging of the Consolidated Financial Statements including notes; ⢠Evaluating the appropriateness of the compa-nyâs use of iXBRL elements selected from the ESEF taxonomy and the creation of extension elements where no suitable element in the ESEF taxonomy has been identified; ⢠Evaluating the use of anchoring of extension elements to elements in the ESEF taxonomy; and ⢠Reconciling the iXBRL tagged data with the audited Consolidated Financial Statements. In our opinion, the annual report of Novozymes A/S for the financial year January 1 to December 31, 2023 with the file name NOVOZYMES-2023-12-31-en.zip is prepared, in all material respects, in compliance with the ESEF Regulation.</arr:AuditorsReportOnXbrlTagging>
<arr:SignatureOfAuditorsPlace contextRef="ctx-1" id="s9_notesesefdkgaap__7__220" xml:lang="en">Hellerup</arr:SignatureOfAuditorsPlace>
<arr:SignatureOfAuditorsDate contextRef="ctx-1" id="s9_notesesefdkgaap__7__221">2024-02-08</arr:SignatureOfAuditorsDate>
<cmn:NameOfAuditFirm contextRef="ctx-51" id="s9_notesesefdkgaap__7__223" xml:lang="en">PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
<cmn:NameOfAuditFirm contextRef="ctx-50" id="s9_notesesefdkgaap__7__222" xml:lang="en">PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
<cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx-50" id="s9_notesesefdkgaap__7__224">33771231</cmn:IdentificationNumberCvrOfAuditFirm>
<cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx-51" id="s9_notesesefdkgaap__7__225">33771231</cmn:IdentificationNumberCvrOfAuditFirm>
<cmn:NameAndSurnameOfAuditor contextRef="ctx-50" id="s9_notesesefdkgaap__7__226" xml:lang="en">Lars Baungaard</cmn:NameAndSurnameOfAuditor>
<cmn:DescriptionOfAuditor contextRef="ctx-50" id="s9_notesesefdkgaap__7__227" xml:lang="en">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
<cmn:IdentificationNumberOfAuditor contextRef="ctx-50" id="s9_notesesefdkgaap__7__228">mne23331</cmn:IdentificationNumberOfAuditor>
<cmn:NameAndSurnameOfAuditor contextRef="ctx-51" id="s9_notesesefdkgaap__7__229" xml:lang="en">Michael Groth Hansen</cmn:NameAndSurnameOfAuditor>
<cmn:DescriptionOfAuditor contextRef="ctx-51" id="s9_notesesefdkgaap__7__230" xml:lang="en">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
<cmn:IdentificationNumberOfAuditor contextRef="ctx-51" id="s9_notesesefdkgaap__7__231">mne33228</cmn:IdentificationNumberOfAuditor>
<gsd:InformationOnTypeOfSubmittedReport contextRef="ctx-1">Annual report</gsd:InformationOnTypeOfSubmittedReport>
<cmn:TypeOfAuditorAssistance contextRef="ctx-1">Auditor's report on audited financial statements</cmn:TypeOfAuditorAssistance>
<gsd:ToolForPreparingTheXBRLInstanceDocument contextRef="ctx-1" xml:lang="en">ParsePort XBRL Converter</gsd:ToolForPreparingTheXBRLInstanceDocument>
<gsd:ReportingPeriodStartDate contextRef="ctx-1">2023-01-01</gsd:ReportingPeriodStartDate>
<gsd:ReportingPeriodEndDate contextRef="ctx-1">2023-12-31</gsd:ReportingPeriodEndDate>
<gsd:PrecedingReportingPeriodStartDate contextRef="ctx-1">2022-01-01</gsd:PrecedingReportingPeriodStartDate>
<gsd:PredingReportingPeriodEndDate contextRef="ctx-1">2022-12-31</gsd:PredingReportingPeriodEndDate>
<gsd:LegalEntityIdentifierOfReportingEntity contextRef="ctx-1">529900T6WNZXD2R3JW38</gsd:LegalEntityIdentifierOfReportingEntity>
<fsa:ClassOfReportingEntity contextRef="ctx-1">Reporting class D</fsa:ClassOfReportingEntity>
<gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx-1">10007127</gsd:IdentificationNumberCvrOfReportingEntity>
<arr:TypeOfModifiedOpinionOnAuditedFinancialStatements contextRef="ctx-1">Opinion</arr:TypeOfModifiedOpinionOnAuditedFinancialStatements>
<arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements contextRef="ctx-1">Basis for Opinion</arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements>
</xbrli:xbrl>